…
…
…
The dynamics of the Hunter syndrome market are anticipated to change in the coming years owing to the launch of…
…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Continued progress on 5x25 strategy to advance five AAV Therapeutics from REGENXBIOs internal pipeline and licensed programs into pivotal-stage or…
read more...…
ROCKVILLE, Md., July 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call…
Latest Ratings for RGNX
DateFirmActionFromTo Mar 2022SVB LeerinkMaintainsMarket Perform Feb 2022SVB LeerinkMaintainsMarket Perform Jan 2022SVB LeerinkMaintainsMarket Perform
…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Latest Ratings for RGNX
DateFirmActionFromTo Mar 2022SVB LeerinkMaintainsMarket Perform Feb 2022SVB LeerinkMaintainsMarket Perform Jan 2022SVB LeerinkMaintainsMarket Perform
…
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…
ROCKVILLE, Md., June 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present and host one-on-one…
Continued progress on 5x25 strategy to advance five AAV Therapeutics from REGENXBIOs internal pipeline and licensed programs into pivotal-stage or…
ROCKVILLE, Md., April 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call…
The company focuses on using its technology for gene-editing therapies....…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
RegenxBio Gets FDA Fast-Track Designation for RGX-202 to Treat Duchenne Muscular Dystrophy...…
ROCKVILLE, Md., March 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming…
Regenxbio (RGNX) delivered earnings and revenue surprises of 6.76% and 12.21%, respectively, for the quarter ended December 2022. Do the…
Continued progress on 5x25 strategy to advance five AAV Therapeutics from REGENXBIOs internal pipeline and licensed programs into pivotal-stage or…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
ROCKVILLE, Md., Feb. 21, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call…
New interim data from Phase I/I/III trial of RGX-121 for the treatment of MPS II and Phase I/II trial of…
RGX-314 produced by the NAVXpress platform process has been well-tolerated and demonstrated a similar clinical profile to the initial adherent…
ROCKVILLE, Md., Feb. 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the SVB…
ROCKVILLE, Md., Feb. 6, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three presentations on RGX-314 will be…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
- Company has initiated Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 - Company also enrolling newly active observational screening study,…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Curran Simpson has been appointed Chief Operating Officer Shiva Fritsch assumes the role of Chief Communications Officer ROCKVILLE, Md., Jan.…
Pakola, Steve - Vorstand - Tag der Transaktion: 2023-01-03...…
ROCKVILLE, Md., Jan. 3, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the 41st…